Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pregabalin
Drug ID BADD_D01835
Description Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter.[A173995] It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions.[A187190] Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels.[A187190][L7066] Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).[L1006][L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.[A31161]
Indications and Usage Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.[L7066]
Marketing Status approved; investigational
ATC Code N02BF02
DrugBank ID DB00230
KEGG ID D02716
MeSH ID D000069583
PubChem ID 5486971
TTD Drug ID D00WUF
NDC Product Code 75834-303; 76282-569; 76282-572; 76420-118; 76420-122; 76420-221; 76420-248; 80425-0025; 80425-0129; 80425-0178; 0904-6991; 0904-7003; 42419-019; 53869-1014; 61294-9991; 64220-169; 65862-761; 65862-790; 0071-1019; 81999-0003; 82924-001; 25000-180; 27808-238; 31722-614; 43353-263; 43353-876; 43547-510; 43598-293; 46708-120; 50228-356; 0228-2859; 55154-8097; 55700-964; 59762-1346; 59762-1348; 59762-1354; 60505-3793; 60687-495; 62332-121; 63629-8208; 64980-410; 65862-759; 65862-760; 67877-466; 67877-469; 68788-7527; 69367-325; 69367-329; 69539-127; 70518-2745; 70518-2763; 71205-323; 71205-556; 71209-034; 71209-037; 71335-1792; 71610-318; 71610-319; 71610-350; 71610-351; 71610-352; 71610-358; 72189-019; 72205-018; 72606-006; 72658-0809; 72658-0849; 76282-568; 76420-095; 76420-117; 80425-0026; 80425-0027; 80425-0030; 80425-0170; 0904-7004; 0904-7005; 53869-1018; 53869-1019; 63415-0121; 66039-926; 0071-1020; 47335-687; 50228-351; 0228-2856; 0228-2860; 60505-3797; 60687-506; 60760-205; 60760-591; 63629-8239; 63629-8248; 64980-416; 68788-7522; 68788-8359; 69238-1315; 69539-012; 69539-016; 70518-3642; 70518-3647; 71335-1758; 71335-2000; 71610-071; 71610-316; 71610-333; 71610-361; 71610-618; 72162-1545; 72162-1548; 72189-115; 72606-007; 72606-008; 80425-0028; 50370-0013; 53869-1012; 53869-1016; 55111-882; 59285-002; 65862-758; 66174-0031; 0071-1012; 27808-235; 31722-610; 31722-615; 43598-297; 46708-124; 46708-125; 47335-692; 47335-693; 0228-2858; 55154-8098; 55700-774; 55700-891; 55700-955; 55700-956; 59762-1342; 59762-1364; 60219-1315; 60760-507; 62135-445; 62135-447; 62332-123; 62332-126; 63629-8196; 64980-413; 64980-415; 67877-464; 67877-467; 67877-468; 69097-957; 69097-961; 69238-1313; 69367-324; 69367-330; 69539-128; 70518-3646; 71205-396; 71205-873; 71209-038; 71335-1505; 71610-320; 71610-365; 71610-619; 71610-719; 72162-1546; 72162-2026; 72189-241; 72205-077; 55700-805; 59762-1360; 60219-1317; 60505-3799; 60760-485; 62135-446; 62332-124; 64980-411; 64980-414; 64980-417; 67877-462; 68788-7521; 68788-8383; 68788-8472; 69097-958; 69097-962; 69238-1311; 70518-2568; 70518-2571; 70518-2892; 70518-2980; 71205-304; 71335-1751; 71335-2012; 71335-9740; 71610-314; 71610-330; 72162-1541; 72162-2024; 72162-2028; 72189-033; 72205-016; 72205-017; 75834-297; 76420-247; 80425-0160; 80425-0307; 0904-7000; 0904-7001; 65862-763; 0071-1014; 0071-1015; 25000-185; 31722-612; 43353-840; 47335-689; 50228-357; 50228-463; 0228-2863; 59762-1344; 59762-1351; 60219-1311; 60505-3795; 60505-3798; 62332-122; 65862-765; 67877-457; 68788-8391; 69238-1316; 69539-015; 70518-2483; 70518-2525; 70518-2762; 71205-298; 71205-694; 71205-733; 71205-874; 71335-1459; 71335-1475; 71335-1762; 71335-9671; 71610-328; 72162-1544; 72189-269; 72189-328; 72658-0811; 76282-575; 76420-119; 76420-121; 76420-123; 80425-0147; 80425-0277; 80425-0308; 0904-6992; 15894-0016; 16812-003; 62331-057; 69218-0300; 27808-239; 27808-241; 31722-616; 31722-617; 43598-291; 43598-298; 47335-691; 50090-6503; 0228-2857; 55700-775; 55700-827; 55700-904; 60219-1310; 62332-120; 63304-047; 63629-8199; 67877-463; 68071-2330; 69238-1310; 69539-011; 69539-018; 69539-129; 71205-608; 71205-872; 71209-039; 71335-1744; 71335-2030; 71335-9699; 72162-1542; 72162-1543; 72189-021; 72189-164; 72205-013; 72205-015; 75834-302; 76420-099; 76420-102; 76420-124; 80425-0116; 0904-7002; 53869-2347; 65862-762; 0071-1013; 0071-1018; 0071-1026
UNII 55JG375S6M
Synonyms Pregabalin | (S)-3-(aminomethyl)-5-methylhexanoic acid | 3-isobutyl GABA | 3 isobutyl GABA | GABA, 3-isobutyl | 3-(aminomethyl)-5-methylhexanoic acid | (R-)-3-isobutyl GABA | (S+)-3-isobutyl GABA | Lyrica | CI 1008 | 1008, CI | CI-1008 | CI1008
Chemical Information
Molecular Formula C8H17NO2
CAS Registry Number 148553-50-8
SMILES CC(C)CC(CC(=O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Histamine intolerance14.02.01.0100.000052%-
Hyperaesthesia teeth07.09.06.005---
Illness08.01.03.0910.009445%-
Inadequate analgesia08.06.01.040; 12.02.20.0060.000861%-
Intermenstrual bleeding21.01.01.015---
Intestinal pseudo-obstruction07.02.02.0200.000052%-
Joint noise15.01.02.0120.000176%-
Morning sickness07.01.07.018; 18.02.02.0220.000052%-
Mucosal disorder08.01.06.029---
Nasal discharge discolouration22.12.03.0110.000052%-
Near death experience17.02.04.023; 19.10.05.0070.000104%-
Oral discharge07.05.05.0310.000052%-
Osteochondrodysplasia03.11.03.002; 15.11.03.002---
Pancreatic failure07.18.02.0110.000052%-
Paralysis recurrent laryngeal nerve12.02.04.014; 17.04.06.005; 22.04.01.0160.000104%-
Phantom limb syndrome08.01.08.033; 17.02.07.0280.000254%-
Potentiating drug interaction08.06.03.0150.000140%-
Primary biliary cholangitis09.01.04.010; 10.04.09.0040.000078%-
Reaction to excipient10.01.01.0420.000140%-
Reversed hot-cold sensation17.02.06.0540.000114%-
Schwannoma16.30.01.013; 17.20.01.0130.000052%-
Spinal stenosis15.10.04.014; 17.10.01.0310.000804%-
Substance use disorder19.07.06.0200.000285%-
Symptom recurrence08.01.03.1010.000052%-
Therapeutic product effect decreased08.06.01.050---
Therapeutic product effect delayed08.06.01.0510.000819%-
Therapeutic product effect incomplete08.06.01.0520.027183%-
Therapeutic product effect increased08.06.01.0530.000052%-
Therapeutic product effect variable08.06.01.055---
Therapeutic response changed08.06.01.0590.000519%-
The 45th Page    First    Pre   45 46    Next   Last    Total 46 Pages